Hope and Challenges: Immunotherapy in <i>EGFR</i>-Mutant NSCLC Patients

Hope and Challenges: Immunotherapy in <i>EGFR</i>-Mutant NSCLC Patients

EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell lung cancer (NSCLC) patients harboring sensitive <i>EGFR</i> mutations. Sadly, remission is transient, and no approved effective treatment options are available for EGFR-TKI-advanced <i>EG...

Full description

Bibliographic Details
Main Author:	Dan Yan
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	Biomedicines
Subjects:	non-small cell lung cancer <i>EGFR</i> mutation immunotherapy
Online Access:	https://www.mdpi.com/2227-9059/11/11/2916

Similar Items

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang Fen, et al.
Published: (2012-08-01)

Efficacy and safety of immunotherapy in EGFR-mutant advanced non-small cell lung cancer: A retrospective study
by: Tingting Tu, et al.
Published: (2023-08-01)

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
by: Kenneth K. W. To, et al.
Published: (2021-05-01)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
by: Yaping Long, et al.
Published: (2022-02-01)

Treatment Strategies for Non-Small Cell Lung Cancer with Common <i>EGFR</i> Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
by: Julian A. Marin-Acevedo, et al.
Published: (2023-01-01)

Concordance of Abundance for Mutational <i>EGFR</i> and Co-Mutational <i>TP53</i> with Efficacy of <i>EGFR</i>-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
by: Youping Wang, et al.
Published: (2023-09-01)

Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review
by: Ran CHEN, et al.
Published: (2022-08-01)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
by: Eric Santoni-Rugiu, et al.
Published: (2019-07-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Yuchen Bai, et al.
Published: (2018-12-01)

Contribution of the Idylla<sup>TM</sup> System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of <i>EGFR</i> Mutations
by: Constance Petiteau, et al.
Published: (2021-11-01)

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis
by: Weiwei Yan, et al.
Published: (2019-09-01)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
by: Albina Kibirova, et al.
Published: (2019-10-01)

Diffuse Lung Metastases in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer
by: Subba R. Digumarthy, et al.
Published: (2019-09-01)

A Nationwide Study on the Impact of Routine Testing for <i>EGFR</i> Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on <i>EGFR</i> Mutation Subclasses
by: Bart Koopman, et al.
Published: (2021-07-01)

An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report
by: Gabriela Chowaniecova, et al.
Published: (2022-12-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

Future Perspectives in Detecting <i>EGFR</i> and <i>ALK</i> Gene Alterations in Liquid Biopsies of Patients with NSCLC
by: Daniela Ferreira, et al.
Published: (2021-04-01)

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
by: Rui Kitadai, et al.
Published: (2022-05-01)

Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
by: Anna Grenda, et al.
Published: (2022-12-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

The Root Extract of <i>Peucedanum praeruptorum</i> Dunn Exerts Anticancer Effects in Human Non-Small-Cell Lung Cancer Cells with Different <i>EGFR</i> Mutation Statuses by Suppressing MET Activity
by: Hyun-Ji Park, et al.
Published: (2022-04-01)

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
by: Jianfeng Peng, et al.
Published: (2021-09-01)

<i>TP53</i> Co-Mutation Status Association with Clinical Outcomes in Patients with <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer
by: Xiuning Le, et al.
Published: (2022-12-01)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
by: Xingxiang Pu, et al.
Published: (2023-10-01)

Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLC
by: Parneet K. Cheema, et al.
Published: (2021-11-01)

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)
by: Vázquez S, et al.
Published: (2016-02-01)

The ways of erlotinib resistance overcoming in treatment of patients with eGFr mutated nsClC
by: S V Orlov
Published: (2013-12-01)

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
by: Xiaolin Ren, et al.
Published: (2024-02-01)

Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
by: Hisao Imai, et al.
Published: (2021-05-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
by: Michael Cekay, et al.
Published: (2023-08-01)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
by: Cristina M. Merkhofer, MD, MHS, et al.
Published: (2021-06-01)

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients
by: Rui-Lian Chen, et al.
Published: (2021-04-01)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
by: Nobuaki Kobayashi, et al.
Published: (2020-08-01)

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
by: Wolfgang Schuette, et al.
Published: (2018-02-01)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
by: Yang Wei, MD, et al.
Published: (2021-07-01)